Iterum Therapeutics Plc – Material Contracts Watch

from 10-Q 26 pages Article 1 Definitions

from 10-Q 7 pages Iterum Therapeutics International Limited License Agreement and US$20,000,000 Amended and Restated Promissory Note

from 10-Q 5 pages Amended and Restated Promissory Note

from 10-Q 45 pages Product Commercialization Agreement

from 8-K 38 pages Securities Purchase Agreement

from 10-K 55 pages Dated December 5, 2024 Iterum Therapeutics International Limited -And- Michael Dunne Amendment to Contract for Services

from 10-Q 48 pages Dated August 9, 2024 Iterum Therapeutics International Limited -And- Michael Dunne Amendment to Contract for Services

from 8-K 3 pages Promissory Note

from 10-Q 16 pages This Agreement Is Dated May 29, 2024 and Made Between: (1) Iterum Therapeutics International Limited Whose Registered Office Is at Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2, D02 Yw24, Ireland (The Company) and (2) Dr. Sailaja Puttagunta With an Address at 39 Buell Hill Road, Killingworth, Ct 06419 (The Contractor) Hereinafter Referred to as the Agreement. Recital the Contractor Has Agreed to Provide the Services to the Company and Any Associated Company Upon and Subject to the Terms and Conditions Hereinafter Contained. It Is Hereby Agreed as Follows: 1. Definitions and Interpretation 1.1. in This Agreement, Unless the Context Otherwise Requires: Associated Company Means Any Holding Company or Any Subsidiary of the Company (As Such Terms Are Defined by Section 7 and Section 8 of the Companies Act, 2014) or Any Subsidiary of Such Holding Company;

from 10-K 50 pages Dated December 27, 2023 Iterum Therapeutics International Limited -And- Michael Dunne Amendment to Contract for Services

from 10-Q 74 pages Dated June 15, 2023 Iterum Therapeutics International Limited -And- Michael Dunne Amendment to Contract for Services

from 10-K 37 pages Dated December 31, 2022 Iterum Therapeutics International Limited -And- Michael Dunne Amendment to Contract for Services

from 10-Q 27 pages Purpose. the Plan, Through the Grant of Awards, Is Intended to Help the Company Secure and Retain the Services of Eligible Award Recipients With an Inducement Material for Such Persons to Enter Into Employment With the Company, Provide Incentives for Such Persons to Exert Maximum Efforts for the Success of the Company and Any Affiliate and Provide a Means by Which the Eligible Recipients May Benefit From Increases in Value of the Ordinary Shares. (D) Definitions. All Capitalized Terms in This Document Are Defined in Section 12 Below. 2. Administration

from 10-Q 28 pages Iterum Therapeutics Public Limited Company Amended and Restated 2018 Equity Incentive Plan

from 10-Q 17 pages Iterum Therapeutics Limited 2015 Equity Incentive Plan Adopted by the Board of Directors: November 18, 2015 Approved by the Shareholders: November 18, 2015 Amended and Restated by the Board of Directors: December 7, 2016 Amended by the Board of Directors: May 17, 2017 Amended by the Shareholders: May 17, 2017 Termination Date: November 17, 2025

from 10-Q 5 pages Share Option Cancellation Agreement

from 10-Q 5 pages Share Option Cancellation Agreement

from 10-Q 32 pages Dated May 25, 2022 Iterum Therapeutics International Limited -And- Michael Dunne Contract for Services

from 10-K 34 pages Iterum Therapeutics US Limited

from 10-Q 2 pages Mr. Michael Dunne 30 Cromwell Place, Old Saybrook, Ct 06475 February 17, 2021 Re: Options and Restricted Share Units Granted Pursuant to the Iterum Therapeutics Public Limited Company 2018 Equity Incentive Plan